Ian Mortimer has been named chief financial officer of biopharmaceutical firm Xenon.
Mortimer previously served as CFO of Tekmira Pharmaceuticals. Before that, he was CFO of Tekmira predecessor Inex Pharmaceuticals.
Researchers from Tekmira Pharmaceuticals last week published new data showing that siRNAs targeting Marburg virus that have been formulated with the company's lipid nanoparticles could provide up to 100 percent post-exposure protection against infection in guinea pig models.
Officials from Alnylam Pharmaceuticals last week provided updates on the company’s pipeline programs, highlighting efforts involving its GalNAc conjugation technology, which enables subcutaneous siRNA delivery, and a fledgling effort in complement-mediated diseases.
Tekmira Pharmaceuticals announced this week that it has launched a phase I/II clinical trial of its siRNA-based cancer therapy TKM-PLK, focusing on two forms of cancer that were particularly responsive to the drug in a previous study.
Tekmira Pharmaceuticals has appointed Mark Kowalski as its chief medical officer.
Before joining Tekmira, he was chief medical officer of YM BioSciences. He joined Gilead Sciences following its acquisition of YM.